Best Peptides for Weight Loss: A Research-Based Guide
Weight loss peptide research has accelerated dramatically since the GLP-1 receptor agonist class demonstrated clinically meaningful outcomes in large-scale trials. But the field extends beyond GLP-1 compounds — researchers are investigating multiple peptide categories that influence body composition through distinct mechanisms including appetite regulation, energy expenditure, fat oxidation, and metabolic signaling.
This guide covers the peptides with the strongest published evidence for metabolic and weight-related research, ranked by clinical data strength.
1. Retatrutide (LY3437943) — The Triple Agonist
Retatrutide produced the most dramatic weight reduction data ever published in an obesity trial. Its triple-receptor mechanism (GLP-1 + GIP + glucagon) represents a fundamentally different approach than single or dual-agonist compounds.
Published data: 24.2% mean weight loss at 48 weeks in the Phase 2 trial (NEJM, Jastreboff et al., 2023). Over 90% of participants lost at least 10% body weight. No weight plateau observed. Phase 3 TRIUMPH-4 reported approximately 71.2 lbs average loss at 68 weeks.
Why it leads: The glucagon receptor component increases energy expenditure and fat oxidation — retatrutide both reduces intake AND increases output. Semaglutide and tirzepatide only reduce intake.
Status: Phase 3 clinical trials. Not FDA-approved. Available for research purposes.
Buy Retatrutide — from $39.99 →
2. Semaglutide — The Established Standard
Semaglutide is the most extensively studied weight loss peptide, with FDA approval for both diabetes (Ozempic) and weight management (Wegovy). As a GLP-1 receptor agonist, it suppresses appetite, delays gastric emptying, and promotes glucose-dependent insulin secretion.
Published data: STEP 1 trial demonstrated approximately 16% mean weight loss at the 2.4mg weekly dose over 68 weeks. Cardiovascular benefit has also been demonstrated, leading to expanded indications.
Limitations: Weight loss typically plateaus, and weight regain is common after discontinuation. Single-receptor mechanism may limit maximum efficacy compared to multi-agonist approaches.
Status: FDA-approved. Available by prescription. Subject to active IP enforcement by Novo Nordisk against grey-market suppliers.
3. Tirzepatide — The Dual Agonist
Tirzepatide (Mounjaro/Zepbound) targets both GLP-1 and GIP receptors, producing greater weight reduction than semaglutide in head-to-head comparisons.
Published data: SURMOUNT trials demonstrated approximately 22.5% mean weight loss at the 15mg weekly dose over 72 weeks.
Advantage over semaglutide: The GIP receptor component enhances insulin response and appears to influence lipid metabolism beyond what GLP-1 alone achieves.
Status: FDA-approved. Available by prescription. Subject to active IP enforcement by Eli Lilly.
How They Compare
| Compound | Receptors | Max Weight Loss | Timeframe | Plateau? |
|---|---|---|---|---|
| Retatrutide | GLP-1 + GIP + Glucagon | 24.2% | 48 weeks | Not observed |
| Tirzepatide | GLP-1 + GIP | 22.5% | 72 weeks | Yes |
| Semaglutide | GLP-1 | 16% | 68 weeks | Yes |
For a detailed mechanism-by-mechanism comparison, see our Semaglutide vs Retatrutide vs Tirzepatide guide.
Beyond GLP-1: Other Metabolic Research Peptides
Growth Hormone Secretagogues
Peptides like CJC-1295, Ipamorelin, and Tesamorelin stimulate growth hormone release, which influences body composition by promoting lipolysis (fat breakdown) and supporting lean mass preservation. While not primarily studied for weight loss, their effects on fat metabolism make them relevant to body composition research. Tesamorelin is FDA-approved specifically for reducing visceral fat in HIV-associated lipodystrophy.
AOD9604
AOD9604 is a modified fragment of human growth hormone (residues 177-191) that has been studied for fat metabolism effects without the full hormonal activity of intact growth hormone. Published research suggests it stimulates lipolysis and inhibits lipogenesis (new fat formation). Results have been mixed in clinical trials, and it has not achieved FDA approval.
Research Availability at PSPeptides
PSPeptides currently carries research-grade Retatrutide — the compound with the strongest published weight reduction data in the GLP-1 agonist class. All product is manufactured in-house in the US at 99%+ verified purity with independent third-party testing.
Retatrutide 5mg — $39.99 | Retatrutide 30mg — $119.99
For complete reconstitution instructions, see our Reconstitution Guide.
References
- Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med. 2023;389(6):514-526.
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(4):327-340.
All products are intended for laboratory research use only. Not for human consumption.
PSPeptides — US Made & Shipped | Third-Party Tested | 99%+ Purity | Same-Day Shipping